Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04770922 · ClinicalTrials.gov registry record

Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia

A clinical trial of Acute Lymphoblastic Leukemia, Pediatric and Adverse Drug Event, sponsored by Cipherome.

Completed
Registry status
80
Enrollment target
1
Study location

NCT04770922 is a study of Acute Lymphoblastic Leukemia, Pediatric and Adverse Drug Event that has completed, run by Cipherome. The registered enrollment target is 80 participants, below the 114-participant average among 8 other Acute Lymphoblastic Leukemia, Pediatric trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04770922, a study of Acute Lymphoblastic Leukemia, Pediatric and Adverse Drug Event, has completed, sponsored by Cipherome.

COMPLETED
Registry status
80 participants
Enrollment target
1
Study location

Study Summary

This is a retrospective biobank study evaluating the impact of novel genetic variants in a population of 6-mercaptopurine treated pediatric acute lymphoblastic leukemia patients.

Study Locations (1)

California

  • Stanford University - Stanford

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2021-02-23
Est. Completion 2021-11-10

Sponsor

Cipherome

5 total trials

What the Registry Record Tells You About NCT04770922

The ClinicalTrials.gov registry entry for NCT04770922 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 114-participant average among 8 other Acute Lymphoblastic Leukemia, Pediatric trials with a reported enrollment target (30% lower). The listed sponsor is Cipherome, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Acute Lymphoblastic Leukemia, Pediatric appearing as the primary indexed condition, and to 0 interventions.

NCT04770922 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04770922 about?

NCT04770922 is a clinical study titled "Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia". This is a retrospective biobank study evaluating the impact of novel genetic variants in a population of 6-mercaptopurine treated pediatric acute lymphoblastic leukemia patients.

What is the current status of trial NCT04770922?

This trial is currently completed. The enrollment target is 80 participants. The study started on 2021-02-23. Estimated completion is 2021-11-10.

What conditions does trial NCT04770922 study?

This clinical trial studies the following conditions: Acute Lymphoblastic Leukemia, Pediatric, Adverse Drug Event.

Who is sponsoring clinical trial NCT04770922?

This trial is sponsored by Cipherome, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04770922 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Lymphoblastic Leukemia, Pediatric

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.